Preventing side effects of bispecific antibody therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether adding a drug called emapalumab can reduce common side effects (cytokine release syndrome and nerve problems) in people receiving bispecific antibody therapy for lymphoma or multiple myeloma. If you're planning to start this treatment, joining may help make it safer and more tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have large B-cell lymphoma or multiple myeloma that has come back or not responded to earlier treatments.
- You are scheduled to receive a bispecific antibody (like epcoritamab or glofitamab).
- Your cancer is measurable (can be seen on scans or tests).
- You have enough organ function (kidney, liver, heart, lungs) and blood counts (neutrophils, platelets, etc.).
- You are not pregnant and agree to use effective birth control during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called CM336 (a bispecific antibody) combined with standard care for people with high-risk multiple myeloma that came back quickly after first treatment. The goal is to see if it helps control the disease better.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
This trial studies new treatments called bispecific antibodies for multiple myeloma, a type of blood cancer. These therapies aim to help patients who have had their disease come back after other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.